Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Patent cliff

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Oct 07, 2021 12:05pm

220 Views

Post# 33982516

RE:RE:RE:Patent cliff

It's another article from industry folks, NASH this time rather than cancer. It seems to me where the market seems to be mostly passing on both THTX's programs that people in industry (and academic KOLs) simply look at it on it's merits. I'm reading a lot into this but I do think that comes from a different way these two groups of people approach this. I think industry partners might follow their peers and at least take a serious look.

SPCEO1 wrote: The article is a bit dated now (it takes so long to get these things published that it is guaranteed to be out of date) but it is still a good overview of the crowded NASH space. Thanks for passing it along.

qwerty22 wrote: https://www.dovepress.com/getfile.php?fileID=73928

Tesa gets a write up.